• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
RGS
Click for more information
33.3% 1.2¢

REGENEUS LTD - Corporate Spotlight

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

A clinical-stage regenerative medicine company using stem cell technologies to develop a... A clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies to address unmet medical needs in human health markets with a focus on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza and Sygenus.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

No Corporate Spotlight currently available.

Top Stories

Unith wraps up Q1 with $5M in cash as digital humans evolve

Unith has wrapped up Q1 of 2024 with nearly $5M in cash and opex reduced. But the bigger story is how good its digital humans are getting.
High grade sniffs in Africa push Mako shares up 14% Mako Gold Ltd (ASX: MKG) has seen its shares jump above 14 percent on news that it has discovered a high grade zone with grades of 76 grams per tonne at its 868,000-ounce Napié Project in Côte d’Ivoire.Shares rose 14.28 percent to 16 cents on Wednesday, as the exploration company ...
Recharged Prospects: 'Watts' on the horizon for copper & lithium The conversation goes much deeper that this title suggests - it explores everything from projections on aluminium & manganese, to what a Donald Trump government could mean for commodities markets.
Lithium Universe eyes hydropower setup for greener battery metals Lithium Universe announced it has made an application in Canada for renewable electricity to power its lithium carbonate plant.
Aus inflation read of 3.6% spooks ASX – before quickly returning to green Australian inflation has come in mixed with an increase of 1% in the March quarter, but a decline from 4.1% in the December quarter.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.